Canada

Sevmia, explained

Sevmia is Apotex's semaglutide for chronic weight management — the first generic of its kind approved in Canada, authorized by Health Canada on June 29, 2026. Where Apo-Semaglutide mirrors Ozempic, Sevmia is the generic counterpart to Wegovy.

Who it's authorized for

Health Canada cleared Sevmia for chronic weight management in adults and adolescents 12 and older who meet the clinical criteria — as an adjunct to diet and activity. Whether it fits you is a decision for your prescriber; this is a description of the authorization, not a recommendation.

The pen

Sevmia is supplied as a multi-use prefilled pen delivering a 1 mg dose. It's the same molecule as the brand product, developed with Orbicular Pharmaceutical Technologies.

Coverage — read the fine print

This is the part people miss: semaglutide for weight management is generally not on public provincial formularies, even now that a generic exists. Most people pay out of pocket or rely on private insurance, and coverage varies plan by plan. Diabetes coverage is a different story from weight-management coverage.

Logging it in Light Years

Choose "Semaglutide (injection)" — Sevmia is listed alongside the other brands. Your weight trend, doses, and history all carry across if you move to or from it.

Sources & last reviewed 2026: Health Canada (Canada.ca); Apotex; CBC News; The Globe and Mail. General information, not medical advice.

Light Years draws this for you, quietly. Open the app or browse the other guides.